Back to top
more

Bioventus (BVS)

(Delayed Data from NSDQ)

$7.17 USD

7.17
327,598

+0.10 (1.41%)

Updated Jul 19, 2024 04:00 PM ET

After-Market: $7.16 -0.01 (-0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner

by Zacks Equity Research

Merck (MRK) exercises the option that will convert the collaboration deal with partner Orion for prostate cancer candidate opevesostat into a license agreement.

Encompass Health (EHC) Expands in Louisville With New Rehab Unit

by Zacks Equity Research

Encompass Health (EHC) and Baptist Health inaugurate a 40-bed inpatient rehabilitation hospital in Louisville, enhancing regional care and expanding EHC's network to 163 facilities.

Here's Why Investors Must Hold on to Centene (CNC) Stock Now

by Zacks Equity Research

Centene (CNC) is expected to benefit from expanding margins in the Marketplace business, contract wins in Medicaid, and improved Medicare Advantage Star ratings.

Compelling Reasons to Hold on to Cigna (CI) Stock for Now

by Zacks Equity Research

Cigna (CI) remains well-poised for growth on the back of improved pharmacy revenues in its Evernorth unit. Solid cash-generating abilities also enable it to tactically deploy capital.

Here's Why You Should Consider Buying Bioventus (BVS) Stock

by Zacks Equity Research

Here, we discuss some reasons why buying Bioventus (BVS) stock now may turn out to be a prudent move.

J&J (JNJ) Seeks Expanded Use of HIV Drug in US and Europe

by Zacks Equity Research

J&J (JNJ) seeks expanded use of its HIV-1 therapy, Prezcobix, for younger kids in the United States and Europe.

Humana (HUM) Partners With UAB to Boost Care for MA Members

by Zacks Equity Research

Humana (HUM) expands its Medicare Advantage network in Alabama through a new partnership with UAB Health System, offering greater access to enhanced healthcare services.

Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody

by Zacks Equity Research

Biogen's (BIIB) Qalsody is the first therapy approved to treat a rare genetic form of ALS in Europe

Merck (MRK) to Buy Private Ophthalmology Company EyeBio

by Zacks Equity Research

Merck's (MRK) acquisition of EyeBio is set to add the latter's lead pipeline candidate, Restoret, a novel Wnt agonist antibody being developed for treating retinal diseases.

J&J (JNJ) to Buy Rights to Novel Atopic Dermatitis Candidate

by Zacks Equity Research

J&J (JNJ) is set to acquire Yellow Jersey Therapeutics, which holds NM26 rights, from Numab's shareholder, for a purchase price of $1.25 billion in cash.

Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock

by Zacks Equity Research

Here, we discuss some reasons why buying Acrivon Therapeutics (ACRV) stock now may turn out to be a prudent move.

Kinjel Shah headshot

5 Small Drug Stocks to Buy From a Recovering Industry

by Kinjel Shah

Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.

Here's Why You Should Retain Centene (CNC) Stock for Now

by Zacks Equity Research

Centene (CNC) remains well-poised for growth on the back of sound growth in membership, divestitures and a growing cash balance.

PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -182.76% and 2.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Bioventus (BVS) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Bioventus' (BVS) third-quarter 2023 earnings call, investors' focus is likely to be on the sales numbers of its three business units - pain treatments, restorative therapies and surgical solutions.

Indrajit Bandyopadhyay headshot

3 Value Medical Stocks to Buy for Safety Amid Market Volatility

by Indrajit Bandyopadhyay

We have narrowed our search to three value stocks from the Medical sector. These are PHG, RDNT and BVS.

Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -30.77% and 3.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1

by Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 100% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of -4% and 41.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for April 5th

by Zacks Equity Research

BVS, BFAM and ESTE have been added to the Zacks Rank #5 (Strong Sell) List on April 5, 2023.

Journey Medical Corporation (DERM) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -62.16% and 4.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ProPhase Labs, Inc. (PRPH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of -500% and 6.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Alpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -51.85% and 73.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Are Options Traders Betting on a Big Move in Bioventus (BVS) Stock?

by Zacks Equity Research

Investors need to pay close attention to Bioventus (BVS) stock based on the movements in the options market lately.

4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -12% and 74.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?